14 July 2017
BD (Becton, Dickinson and Company)
BD (Becton, Dickinson and Company) has committed to utilize extensive cross-sector collaboration to develop, clinically test, manufacture, and distribute at scale – at favorable conditions in low resource settings – new innovations designed to address leading causes of maternal and newborn mortality and morbidity. The first commitment utilizing this model, presently in clinical studies, is the BD Odon Device™, a new low-cost device for assisted vaginal delivery during circumstances of intrapartum complications, with potential for application by mid-level providers. The investment commitment for this innovation is US$15 – $20 million.
At the Every Woman Every Child Private Sector Innovation Working Group event on 25 September 2015, BD announced a new, second innovation involving a ground-breaking collaboration with the Global Health Investment Fund (GHIF). Under this first-of-its-kind arrangement, the GHIF is providing R&D financing and BD is making a balance sheet investment to develop and commercialize new low-cost point-of-care tests to diagnose leading, life threatening complications of pregnancy. The Bill & Melinda Gates Foundation is providing financial support to help ensure any successfully developed products have the best possible chance of reaching those most in need. The investment commitment for development of these tests is US$25 – $30 million. These maternal and newborn health innovations will be developed in the 2015 – 2020 time frame.
The implementation of the clinical evidence generation plan for the BD Odon Device , including preclinical and clinical studies, was initiated during the last year. Four preclinical studies (animal, simulation and Human Factors studies) have been completed to inform the process of product development before clinical testing. All studies achieved predefined objectives and all acceptance criteria that are required before testing the device in humans have been met. In addition, the final version of the BD Odon Device for use in clinical trials has been finalized and the pilot clinical trial is expected to start in April 2017.
2014-Every Newborn Action Plan
BD (Becton, Dickinson and Company) commits to leading and engaging in an innovative business model utilizing extensive cross-sector collaboration to develop, clinically test, manufacture, and distribute – at favorable conditions in low resource settings – new innovations designed to address the leading causes of maternal and newborn mortality and morbidity. This proposed collaborative partnership approach involves a series of aligned responsibilities and accountabilities, including shared financing commitments oriented toward the common goal of reducing maternal and newborn mortality. BD will engage with multilateral partners, academic institutions, international agencies, professional societies, and non-governmental organizations. Funding organizations, including foundations and private investor groups, will support these developments with seed funding utilizing a reimbursable model. Governments and foundations will support access in high burden countries through grants and market guarantees.
The first innovation utilizing this model, presently in clinical studies, is the BD Odon Device™, a new low-cost device for operative vaginal delivery during circumstances of intrapartum complications, with potential for application by mid-level providers. These claims are subject to completion of clinical studies. BD is presently evaluating other maternal and newborn health innovations with the intent to pursue scale development, manufacturing, and distribution utilizing this collaborative business model.
Becton Dickinson commits to be a participating partner in ‘Together For Girls,’ with UNICEF, UNAIDS, UNFPA and UNIFEM, private sector organizations and the US government to help the UN drive forward solutions towards ending sexual violence against girls.
Learn More about BD
· National Violence Against Children Surveys (VACS) have been conducted
in nine countries (Swaziland, Tanzania, Kenya, Zimbabwe, Indonesia, Cambodia, Haiti, Nigeria and Malawi), providing, in several countries, the first ever nationally available data on emotional, physical and sexual violence against girls and boys, contributing greatly to understanding the scale of the problem, the link to gender inequality and HIV, and risks and protective factors for children.
· Following completion of the VACS, Kenya’s Child Protection Centers (CPCs) were established and have reached well over 2,000 children through counseling and referrals, with 4,000 key personnel trained in building child protection systems in Tanzania.
· While it is still too early to evaluate reductions in violence, comprehensive national actions for the prevention and response to violence against children,
as well as instigating changes in laws or law enforcement, interventions in schools and communities are being implemented in Swaziland, Tanzania, Kenya, and Zimbabwe.